These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 18767165

  • 1. Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors.
    Katayama N, Orita M, Yamaguchi T, Hisamichi H, Kuromitsu S, Kurihara H, Sakashita H, Matsumoto Y, Fujita S, Niimi T.
    Proteins; 2008 Dec; 73(4):795-801. PubMed ID: 18767165
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM.
    Proteins; 2007 Mar 01; 66(4):912-29. PubMed ID: 17173284
    [Abstract] [Full Text] [Related]

  • 4. Activity prediction and structural insights of extracellular signal-regulated kinase 2 inhibitors with molecular dynamics simulations.
    Del Rio A, Baldi BF, Rastelli G.
    Chem Biol Drug Des; 2009 Dec 01; 74(6):630-5. PubMed ID: 19843074
    [Abstract] [Full Text] [Related]

  • 5. Strong and weak hydrogen bonds in protein-ligand complexes of kinases: a comparative study.
    Panigrahi SK.
    Amino Acids; 2008 May 01; 34(4):617-33. PubMed ID: 18180869
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper.
    Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, Powers JP, Walker NP.
    Structure; 2006 Dec 01; 14(12):1835-44. PubMed ID: 17161373
    [Abstract] [Full Text] [Related]

  • 10. Molecular modeling and crystal structure of ERK2-hypothemycin complexes.
    Rastelli G, Rosenfeld R, Reid R, Santi DV.
    J Struct Biol; 2008 Oct 01; 164(1):18-23. PubMed ID: 18571434
    [Abstract] [Full Text] [Related]

  • 11. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
    Xing L, Shieh HS, Selness SR, Devraj RV, Walker JK, Devadas B, Hope HR, Compton RP, Schindler JF, Hirsch JL, Benson AG, Kurumbail RG, Stegeman RA, Williams JM, Broadus RM, Walden Z, Monahan JB.
    Biochemistry; 2009 Jul 14; 48(27):6402-11. PubMed ID: 19496616
    [Abstract] [Full Text] [Related]

  • 12. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
    Wichapong K, Lindner M, Pianwanit S, Kokpol S, Sippl W.
    Eur J Med Chem; 2009 Apr 14; 44(4):1383-95. PubMed ID: 18976834
    [Abstract] [Full Text] [Related]

  • 13. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex.
    Ohori M, Kinoshita T, Okubo M, Sato K, Yamazaki A, Arakawa H, Nishimura S, Inamura N, Nakajima H, Neya M, Miyake H, Fujii T.
    Biochem Biophys Res Commun; 2005 Oct 14; 336(1):357-63. PubMed ID: 16139248
    [Abstract] [Full Text] [Related]

  • 14. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening.
    Park H, Bahn YJ, Jeong DG, Woo EJ, Kwon JS, Ryu SE.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5372-6. PubMed ID: 18835158
    [Abstract] [Full Text] [Related]

  • 15. [Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research].
    Holm M, Lehmann F, Laufer S.
    Pharm Unserer Zeit; 2008 Oct 15; 37(5):382-92. PubMed ID: 18729263
    [No Abstract] [Full Text] [Related]

  • 16. A pharmacophore map of small molecule protein kinase inhibitors.
    McGregor MJ.
    J Chem Inf Model; 2007 Oct 15; 47(6):2374-82. PubMed ID: 17941626
    [Abstract] [Full Text] [Related]

  • 17. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
    Charrier JD, Miller A, Kay DP, Brenchley G, Twin HC, Collier PN, Ramaya S, Keily SB, Durrant SJ, Knegtel RM, Tanner AJ, Brown K, Curnock AP, Jimenez JM.
    J Med Chem; 2011 Apr 14; 54(7):2341-50. PubMed ID: 21391610
    [Abstract] [Full Text] [Related]

  • 18. Implications for selectivity of 3,4-diarylquinolinones as p38alphaMAP kinase inhibitors.
    Peifer C, Urich R, Schattel V, Abadleh M, Röttig M, Kohlbacher O, Laufer S.
    Bioorg Med Chem Lett; 2008 Feb 15; 18(4):1431-5. PubMed ID: 18207396
    [Abstract] [Full Text] [Related]

  • 19. Bisubstrate analog probes for the insulin receptor protein tyrosine kinase: molecular yardsticks for analyzing catalytic mechanism and inhibitor design.
    Hines AC, Parang K, Kohanski RA, Hubbard SR, Cole PA.
    Bioorg Chem; 2005 Aug 15; 33(4):285-97. PubMed ID: 16023488
    [Abstract] [Full Text] [Related]

  • 20. Conformational analyses and MO studies of f152A1 and its analogues as potent protein kinase inhibitors.
    Ikemori-Kawada M, Kawai T, Goto M, Wang YJ, Kawakami Y.
    J Chem Inf Model; 2009 Dec 15; 49(12):2650-9. PubMed ID: 19995092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.